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Cell culture technology is used to model structural and functional properties of human organs under normal and 
pathological conditions “in a dish”. The most obvious reason to culture human breast-derived cells is our 
fundamental desire to understand and ultimately treat breast cancer. Highly reproducible serum-free 
formulations for long-term propagation of normal human breast epithelial cells have existed for more than three 
decades and have served to complement the insight gained from a vast number of established breast cancer cell 
lines. The unspoken dichotomy in the experimental approach, however, has lied in the puzzling fact that 
normal-derived cells show a more myoepithelial expression profile, while breast cancer cells show more of a 
luminal profile making these difficult to compare experimentally. Moreover, normal estrogen receptor positive 
(ER+) luminal cells, thought to be equivalents to the most frequent form of human breast cancer, the ER+ 
subtype, completely fail to grow under standard culture conditions. One might choose to ignore this fact since 
breast homeostasis relies on a stem cell hierarchy and stem cells reside in the myoepithelial compartment which, 
if given the right conditions, can differentiate into ER+ luminal cells. The problem with this is that myoepithelial 
cells in culture, for unknown reasons, fail to behave like myoepithelial cells in vivo. This review summarizes 
some of the progress that has been made in the field with regard to the ER+ luminal breast epithelial lineage, 
especially within a human context, and its relevance to human breast cancer. 
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Introduction 
Almost thirty years ago Pierce and Speers published the 
landmark review “Tumors as caricatures of the process of 
tissue renewal: prospects for therapy by directing 
differentiation” [1]. This hypothesis, that tumors reflect an 
aberrant differentiation regime, was developed based on the 
assumption that cancer stem cells emerge from normal stem 
cells with the capacity for terminal differentiation. Indeed, 
experimental evidence has been provided for a stem cell 
origin of cancer cells in tissues with rapid cellular turnover 
[2]. Whether this is also the case in tissues with relatively 
slow cellular turnover, such as in the human breast, remains 
an open question. It has been argued that the requirements 
for normal cells to be susceptible to tumor initiation are 
fulfilled if the cells divide asymmetrically, and if one of the 
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progeny remains long enough in the tissue to sustain and 
accumulate oncogenic mutations [3]. Aside from breast stem 
cells residing in the myoepithelial compartment [4], at least 
one other luminal cell type presumably stays long enough in 
the tissue to become classified as a candidate precursor cell, 
namely the label-retaining ER+ cell [5]. 
In line with this insight, breast cancer classification 
increasingly relies on taxonomy based upon normal cell 
phenotypes [6]. Furthermore, subtype-specific cell-of-origin 
hypotheses are integrated into emerging stem cell hierarchies 
of the human breast [7-9]. For these reasons, the ER+ cell in 
the normal human breast becomes increasingly important if 
we wish to understand the evolution of the most frequent 
type of human breast cancer i.e. the ER+ subtype. The 
generation of ER+ breast cancer still poses many questions in 
the field. Is ER+ breast cancer derived from an ER+ normal 
equivalent or a candidate precursor cell? At what level of 
differentiation within the hierarchy can ER+ breast cancer 
develop? In mice, ER+ tumors develop from both luminal 
and myoepithelial cells-of-origin if destabilized by oncogenic 
PI3K [10, 11]. However, tumors originating in mice are not 
similar to typical human luminal breast cancer [12, 13]. 
Questions such as these require normal cell culture models 
that can be sequentially transformed faithfully imitating a 
luminal breast cancer subtype, most importantly, by using 
human cells. Attempts to reach this goal have been hampered 
by the relatively low number of ER+ cells in the human 
breast [14], lack of surface markers for prospective isolation, 
as well as the reluctance of luminal cells in general and ER+ 
cells in particular, to proliferate in culture [15]. Here I will 
focus on contemporary insights in ER+ cells, drawing from 
rodent models only if relevant for the human context. 
Estrogen receptor positive cells: A relay between systemic 
hormones and tissue specific function 
Most organs in the human body are patterned and are fully 
developed at the time of birth. The human breast is also 
patterned embryonically with distinctly arranged hormone 
sensing cells however, ER+ cells are primarily active 
between the onset of puberty and menopause in females [16]. 
During this phase of life, the human breast is submitted to 
monthly cycles of circulating sex hormones only interrupted 
by pregnancies and subsequent lactation. These phases are 
largely choreographed through the ovarian hormone 
responsive ER+ and progesterone receptor positive (PR+) 
cells [17]. 
Understanding the relevance of ER+ cells requires a brief 
summary of their place in breast anatomy. Through the 
development of the breast, the bilayered epithelium consists 
of 15-25 ducts that originate from the nipple and end in 
terminal ductal-lobular units (TDLUs), the effective 
functional units of the breast. The epithelial compartment is 
segmented into ducts and lobules which act together to 
provide nutrients to the newborn. The outer layer is 
composed of myoepithelial cells which provide contractile 
capacity for milk ejection. The inner luminal layer is 
responsible for tissue specific milk secretion. Important 
markers for the myoepithelial layer include alpha smooth 
muscle actin (αSMA), cell surface antigen Thy1, 
transcription factor p63, and cytokeratins K5, K14 and K17. 
Luminal cells are marked by an epithelial cell adhesion 
molecule (EpCAM or CD326), a transmembrane 
glycoprotein sialomucin (MUC1 or MAM6), as well as the 
cytokeratins K7, K8, K18 and K19 [18-21]. The luminal 
epithelial compartment in both ducts and lobules is 
seemingly more heterogeneous than the myoepithelial 
compartment and is thought to be comprised of multiple 
cellular subsets with distinct functionality [6, 20, 22]. 
More comprehensive identification and characterization of 
the cells within the luminal lineage would allow us to gain a 
better understanding of their functional role in the tissue. 
There is good reason to assume that the ER+ (and PR+; see 
below) hormone sensing cells act as critical relay cells for the 
hormonal control of the cyclic cellular growth seen in this 
tissue. However, in the absence of cellular models, it has 
been difficult to unequivocally assess whether estrogen acts 
as a bona fide mitogen on its own under homeostatic 
conditions in the human breast. 
There is extensive indirect evidence in humans for an 
effect of estrogen in the tissue, suggesting that it is an 
important player in breast epithelial growth and 
differentiation. This evidence is based on both clinical data 
as well as various mouse models [23-27]. Clinical evidence 
shows that rare genetic aberrations resulting in aromatase 
deficiencies, impairing estrogen biosynthesis, lead to the 
masculinization of the female external genitalia at birth due 
to the inability to convert androgens to estrogens [23, 24]. 
Initially, breast development is normal in these patients. 
However, affected females fail to undergo normal breast 
development at puberty. Estrogen replacement therapy for 
these patients initiates sexual maturation, highlighting the 
importance of estrogen and ER+ cells in breast development 
in humans. Similarly, ovariectomized or ER knockout mice 
fail to fill the fat pad with mammary ducts, showing that 
estrogen signaling is crucial for ductal epithelial growth 
during puberty [25-27]. Whereas these original studies 
associate estrogen and ER+ cells with growth, exactly how 
this is conveyed at the tissue level was a mystery due to the 
fact that ER+ cells themselves appear to be post-mitotic [14, 
28]. However, meticulous double labeling experiments 
revealed that proliferation marker Ki67 and the ER are 
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expressed in different albeit often neighboring cells [29, 30]. 
This observation has since been confirmed by others [27, 31, 32]. 
This suggests that estrogen might acts in a paracrine manner 
by acting on ER+ cells which then exert proliferating signals 
to neighboring cells. Indeed, it has been shown that the 
EGFR ligand, amphiregulin (AREG) is one such mediator 
[33]. Upon hormone stimulation, AREG is released by ER+ 
cells and acts as a proliferative factor on neighboring cells. 
Aside from morphogenic properties during puberty, estrogen 
is also necessary for priming the gland for lobular and 
alveolar differentiation during pregnancy and lactation, at 
least in mice [32]. 
The majority of ER+ cells also express progesterone 
receptor (PR), which has also been shown to be a crucial 
factor for full mammary development in addition to estrogen 
[28]. However, the cellular proliferative response to 
progesterone is quite different from the proliferative response 
to estrogen [34]. PR knockout mice undergo normal ductal 
elongation during puberty, but lack secondary branches and 
display a complete absence of alveolar development upon 
pregnancy [35]. Progesterone signaling seemingly mediates 
the expansion of mammary alveoli into lobules 
(alveologenesis) during puberty and pregnancy in preparation 
for lactation [36]. Studies in ovariectomized mice show that 
RANKL, a downstream target of PR, mediates a growth 
signal to myoepithelial cells which express its receptor 
RANK to convey proliferative signals [37, 38]. However, it has 
to be pointed out, that the paracrine signaling of the 
RANK/RANKL pathway in mice is different in a human 
context as discussed below. Nevertheless, based on mice 
studies it is clear that estrogen, together with progesterone 
signaling depends on paracrine mechanisms to convey 
mitotic signals but it remains to be answered how estrogen 
and ER mediate these signals within the context of the 
human breast. 
Understanding ER in humans: current and future models 
of ER+ cells in culture 
Experimentally, the characteristics and function of normal 
ER+ cells have been studied immensely in the intact mouse 
mammary gland. However, for obvious ethical reasons, 
similar experiments cannot be performed in humans. Instead, 
experimental insight in human ER+ cells has been obtained 
to a limited extent from short-term cultures with primary 
normal tissue, but to a far larger extent from established cell 
lines, isolated entirely from breast cancer. It is important to 
emphasize that unlike the normal homeostatic breast gland, 
where ER is expressed in only a subset of luminal cells [14], 
ER+ breast cancer is composed of a much larger degree of 
ER+ luminal-like cells. This brings into question whether 
normal ER+ cells behave and respond to estrogen stimulation 
in the same way as ER+ cancer cells. Despite this difference, 
many conclusions made about the mode of action of estrogen 
and ER+ cells in the human breast have been deduced from 
data obtained on ER+ breast cancer cell lines. Moreover, 
although approximately 17 ER+ cell lines [39] are available 
from the American Type Culture Collection (ATCC) cell line 
repository, only a handful of cell lines are widely used, 
notably the cell lines MCF7 [40], T47D [41] and ZR-75-1 [42]. 
These ER+ cell lines have been isolated predominantly from 
late metastatic lesions of breast cancer. The MCF7 cell line, 
specifically, is by far the most widely utilized and was 
derived from a pleural effusion. This cell line has been 
extensively referenced for ER-related research, detailing the 
intricate binding of estrogen to its cognate receptor as well as 
the gene expression programs triggered by estrogen 
stimulation [43]. Although the binding properties of estrogen 
to the ER in MCF7 cells shows consensus in various 
laboratories [44], the gene expression programs initiated by 
estrogen in this cell line have shown variation in different 
studies [45, 46]. Multiple reasons may contribute to this 
variation, including the culture history of the cell line, 
varying culture conditions, duration of estrogen treatment, as 
well as bioinformatics used for analysis [47]. Whether ER+ 
cells in the normal gland will respond in a similar way as to 
MCF7 after hormone stimulation can, at the moment, only be 
speculated. This is due to the lack of appropriate culture 
models supporting proliferation and maintenance of 
lineage-characteristics of normal ER+ cells. Establishment of 
such a system will allow us to study for the first time the 
hormonal effect of both estrogen and progesterone in a 
normal context and more importantly, how they differ in 
ER+ breast cancer. 
ER+ cells have been prospectively isolated from mouse 
mammary glands with a number of different protocols [48-50]. 
However, while it is tempting to extrapolate data gathered 
from mice to a human context, this is not always feasible or 
scientifically sound. Firstly, not all the markers in the mouse 
mammary gland are expressed in the human breast. For 
instance, humans have been shown to lack Sca-1, a widely 
used marker of differentiated luminal cells in the mice [48]. 
Similarly, prominin-1 is not restricted in humans to ER+ 
cells as in the mouse mammary gland, but rather presented 
on the apical surface of all luminal cells [51]. One might think 
such details are unimportant when it comes to gross 
physiology. However, we simply may not yet have seen the 
full picture of the species specific differences. Secondly, 
signal transduction pathways can differ between species, in 
part, due to the different distribution of ligands and their 
receptors as well as a sensitivity of signaling itself. For 
example, in the mouse mammary gland, one of the 
downstream effectors of progesterone, RANKL, triggers 
RANK signaling within the myoepithelial compartment [37, 
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38]. Conversely, in the human breast RANK positive cells are 
mainly located in luminal progenitors [52]. Thirdly, while the 
pivotal role of ER in the human breast is quite obvious, an 
additional layer of complexity arises from potential 
epithelial-stromal signaling [53]. Unfortunately, mouse 
models do not accurately reflect the tissue context of the 
stroma in the human breast. The stromal compartment of the 
mouse mammary fat pad is predominantly composed of 
adipocytes and contains relatively few fibroblasts compared 
to the human breast. In humans, the TDLUs are characterized 
not only by their epithelial components but also by the 
presence of a specialized intralobular stroma [18, 55]. The 
fibroblast component develops together with the epithelium 
and presumably provides signaling cues throughout 
development and tissue homeostasis [56]. The TDLUs, in turn, 
are surrounded by a denser extra-lobular stroma composed 
predominantly of collagen. This is in contrast to mice in 
which epithelial structures grow into surrounding adipose 
tissue. Both the intra- and extra-lobular fibroblast-generated 
matrices provide secretory enzymes and cytokines that upon 
activation have morphogenic roles which contribute to 
epithelial development and homeostasis [56-58]. Whether the 
anatomical differences seen between human and mice 
translate to differences in the proliferative capacity with 
regard to estrogen or progesterone signals are less known. 
Not only are there obvious anatomical differences but also, 
estrogen specific signaling differences. For example, unlike 
human fibroblasts, mouse fibroblasts express ER [54]. 
Therefore, the stroma must be considered when comparing 
species with respect to relaying circulating levels of estrogen 
into tissue specific function. One could speculate that indeed 
the anatomical difference between intralobular and 
interlobular stroma in the human breast is provided by 
different fibroblast lineages, like it has been demonstrated for 
the different stromal compartments within the skin of mice 
[59, 60]. If correct, fibroblast compartmentalization may have a 
more significant impact on epithelial structure and function 
than previously thought, and may play a more decisive role 
in tumor initiation. 
Clean separation of the epithelial cells is also of great 
importance. Cell sorting protocols and technologies have 
improved in the last two decades and in turn, have facilitated 
to a great extent the characterization of various cell types, 
including human breast epithelial cells. Magnetic-activated 
cell sorting (MACS) as well as fluorescence activated cell 
sorting (FACS) based strategies emerged as an efficient way 
for lineage separation. While the cell sorting technologies 
have themselves been improved significantly, the repertoire 
of lineage-specific surface markers in the human breast has 
expanded rather slowly. For the two lineages of the breast 
epithelium isolation was originally based on exclusive 
expression of epithelial membrane antigen (EMA or MUC1) 
for cells in the luminal compartment and the common acute 
lymphoblastic leukemia antigen (CALLA, or CDl0) for cells 
in the myoepithelial compartment [19, 61, 62]. Later, as a 
modification of the mouse lineage markers CD24 and CD49f 
[63], EpCAM and CD49f were adapted to enrich luminal and 
myoepithelial cells, respectively in the human breast [20]. 
Among the EpCAM+ cells, CD49f expression can be used as 
a marker to enrich the luminal progenitor populations 
(EpCAM+/CD49fhi) from more mature luminal cells 
(EpCAM+/CD49flow/-) [20, 64-66]. However, none of these 
markers facilitated the isolation of relatively clean 
populations of ER+ cells which have been done in mice. 
Instead, ER+ cells have been studied in short term culture 
systems made of either mixed cell cultures containing both 
luminal and myoepithelial cells at various differentiation 
stages or as organoids where physiological tissue architecture 
remains intact. 
These initial attempts have shown that human ER+ cells 
were responsive to estrogen if excised from the tissue and 
placed in primary cell cultures [67]. Importantly, however, 
enriched populations of ER+ cells using this approach did 
not maintain their ER expression in culture. In a more recent 
study, organoid culture conditions maintained functionally 
relevant ER expression up to 5 days, where the hormone 
response was maintained as evidence by RANKL expression 
after progesterone stimulation, which then induced a 
proliferative response as expected [68]. With cells from mice, 
it has been shown that cultivation inside a three-dimensional 
basement membrane delays the loss of ER [69]. However, in 
our hands, this does not apply to human cells (unpublished 
observation). Another established non-malignant-derived 
ER+ cell line comes from the 184 series [70] which has been 
immortalized with benzo(a)pyrene and eventually fully 
transformed in severely immunodeficient NOG mice [71]. 
While such cell lines have provided important insights, the 
exact relations to normal cells in terms of ER signaling has 
remained obscure [72]. Progress was recently made in this 
area by our group by isolating ER+ cells and maintaining ER 
expression in cells culture from normal-derived human breast 
tissue [73]. These attempts were successful due to the 
utilization of markers to identify ER+ cells. By 
immunohistological identification of novel markers, which 
co-localized specifically with ER+ cells, the luminal lineage 
could be separated further by FACS into luminal progenitors 
and differentiated ER+ cells by using subpopulation-specific 
surface markers. The first initial attempt used 
carcinoembryonic antigen-related cell adhesion molecule 6 
(CEACAM6 or CD66c) which was shown to be associated 
with the luminal ER and PR cell populations in the normal 
breast tissue, predominantly in TDLUs [74]. Analysis of 
proliferative markers and an absence of proliferation in 
cultured cells suggested that CEACAM6 is predominantly 
Receptors & Clinical Investigation 2016; 3: e1449. doi: 10.14800/rci.1449; © 2016 by Branden M. Hopkinson 
http://www.smartscitech.com/index.php/rci 
 
Page 5 of 9 
 
expressed in post-mitotic mature ER+ cell populations. A 
second attempt used the cell surface marker activated 
leukocyte cell adhesion molecule (ALCAM or CD166) 
which was also shown to be highly associated with ER 
expression and has since been used efficiently for the 
enrichment of ER+ cells by FACS [73]. Once isolated and in 
culture, ER expression fluctuated and therefore a marker to 
track these cells was needed. This was achieved by the 
antigen recognized by the Ks20.8 antibody, which acted as a 
surrogate marker with a longer half-life than the ER in 
culture. Importantly, Ks20.8 was shown to be highly 
associated with the majority (about 90%) of ER and PR 
expressing cells in ducts and lobules and therefore served as 
an excellent candidate to track these cells in culture [73]. 
Regardless of efforts to identify markers that allow 
isolation of these ER+ cells, ER expression of primary cells 
has been difficult to maintain in culture as these cells were 
shown to lose ER expression and undergo growth restriction 
[68, 69, 75]. The ability to circumvent these complications was 
deduced from previous observations made by Ewan et al [29, 
30]. Specifically, these studies identified some of the critical 
components facilitating the growth inhibition in vivo of ER+ 
cells, namely TGFβ signaling. In mice, TGFβ signaling has 
been shown to influence mammary gland development [76]. 
ER and TGFβ signaling elicit distinctly opposing roles on 
mammary epithelial proliferation. While ER signaling 
promotes survival and proliferation within the luminal 
epithelial compartment, these cells were shown to be highly 
sensitive to TGFβ-induced cell cycle arrest. Around the time 
of puberty in mice, the rise of estrogen inhibits TGFβ 
signaling within the luminal compartment along the ductal 
epithelium resulting in an increase in proliferation [29, 76]. The 
ER and TGFβ signaling networks have been shown to 
interact directly though TGFβ-SMAD signaling components 
[30]. TGFβ depletion alone does not trigger epithelial 
proliferation but releases epithelial cells from growth 
restraint, while proliferative signals are still initiated and 
maintained by ovarian hormones or other proliferative 
stimuli. Upon estrogen stimulation, TGFβ signaling is 
uniformly repressed and ER- luminal cells proliferate [29]. 
Paradoxically, some ER+ cells increase TGFβ signaling in an 
autocrine manner. This results in the emergence of a 
population of non-proliferative ER+ cells amongst the 
proliferating luminal population [30]. This autocrine TGFβ 
signaling, shown to inhibit cell proliferation specifically in 
luminal ER+ cells, was seemingly responsible for the lack of 
success in culturing an ER+ luminal cell population. After 
isolating ER+ cells from normal human primary tissue using 
the lineage-specific markers (EpCAMhi/CD271low/CD166hi/ 
CD117low), down-regulation of ER expression and growth 
restraint was released by small molecule inhibitors against 
TGFβR, presumably breaking an anti-proliferative autocrine 
loop [73]. More importantly, these prospectively isolated ER+ 
cells showed a proliferative response to estrogen suggesting 
an intact functional hormone sensing signaling program. For 
the first time, we could now begin to design experiments 
aimed at comparing these novel normal-derived ER+ cells 
with the cancer-derived ER+ cell lines previously available. 
Developing a relevant model of normal ER+ cells for 
breast cancer research 
Once established in primary culture, we wanted to 
establish stable ER+ cell lines to further pursue the ideal 
clean comparisons with MCF7 cells as envisioned above. 
Obviously, developing culture conditions designed to extend 
cellular life span in culture without having to integrate 
genetic alterations was preferred. However, eventually, such 
cells meet a stress-associated stasis barrier and replicative 
senescence due to critically shortened telomeres and are 
therefore subject to a limited number of cell divisions [77]. 
This limits the capacity for cell growth and thus material for 
experimentation. Hence, it was necessary to explore the 
possibilities for cell immortalization. Immortalization, in 
theory, establishes indefinite proliferation and generates 
essentially infinite material for experimentation [78]. 
Spontaneous immortalization does not occur readily in 
human cell cultures [79]. They have been, on rare occasion 
established “spontaneously” from patients with benign breast 
disease such as HMT3522 [80] and MCF10A [81]. However, 
due to the infrequency of these events immortalization 
strategies are employed. Previous successfully applied 
immortalization strategies have included introduction of viral 
oncogenes such as SV40 or E6/E7 [19, 82, 83], or of specific 
genes, such as hTERT [84], CCND1/c-MYC [85], 
shp16/c-MYC [77] and combinations thereof. While 
previously immortalized breast cells mostly displayed the 
desired luminal phenotype, they lacked relevant ER 
expression. Therefore, to immortalized the ER+ cells from 
normal primary tissue we employed a combination of hTERT 
and shp16, which has shown to be less aggressive compared 
to viral oncogenic immortalization, with the aim of 
maintaining the luminal phenotype and most importantly, ER 
expression. Indeed, upon selection for the relevant integrated 
vectors, normal-derived cell-lines emerged which could be 
kept long-term in culture [73, 86]. Single cell clones were 
generated from the parent populations of these ER+ 
immortalized cells and remained ER+ and for the most part, 
responsive to estrogen. However, these cells were prone to 
drifting towards a myoepithelial phenotype. Thus, while 
un-immortalized cells remain essentially luminal by our 
standard criteria, immortalized cells lines after selection quite 
often express myoepithelial markers such as αSMA, K14 and 
p63 along with the classical luminal markers. This was 
unacceptable given our initial aim of having a lineage 
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equivalent to MCF7. Additionally, it is worthwhile to 
mention that breast cancer, in general, differentiates along 
the luminal epithelial lineage [87]. In our hands, the most 
reliable luminal markers of the luminal epithelial lineage is 
K19 followed by MUC1 [73, 86]. However, certain subtleties 
should be particularly observed when dealing with cells in 
culture and for this reason, we take advantage of different 
staining patterns by numerous K19 antibodies. Whereas K19 
antibodies seem to stain the luminal cells almost identically 
in situ, in cultured cells staining patterns differ when 
different K19 antibodies were applied. For example, we have 
previously used the A53-B/A2 clone of K19 antibody [19]. In 
later screens of our antibody library, we realized that this 
clone stains cultured cells much broader than other clones 
such as BA16 [87]. We have evidence that BA16 is limited to 
the near-mature luminal phenotype, while A53-B/A2 also 
stains intermediate or early stages of luminal differentiation. 
On the other hand, the myoepithelial lineage marker K14 has 
been used by us and others to demonstrate cells of the 
myoepithelial lineage in culture [20, 84]. One feature of K14 is 
that its expression is induced quite broadly in cells of the 
luminal epithelial lineage somewhat depending on the culture 
medium used. We found that it was expressed in most 
normal-derived cell-lines of the hTERT/shp16 transduced 
ER+ cells presumably as a result of a drifting phenotype 
(unpublished observation). Again this was unacceptable 
since, unlike K19 which is typically expressed in human 
breast cancers, K14 is quite rare in human breast cancer. To 
circumvent the culture-induced drift, we re-sorted the cells 
repeatedly with the cell surface marker CD146 [86]. Using this 
approach we obtained cell lines which were K19+/K14-, as 
well as MUC1+. Thus, we were successful in generating a 
normal derived ER+ immortalized cell line. In attempts to 
pursue a clean comparison to MCF7, we wanted to uniform 
culture conditions between the two cell lines. However, 
MCF7 cells did not readily adapt to the normal ER+ culture 
conditions TGFbR2i in Fridriksdottir et al [73]. After 
screening different conditions, we developed TGFβR2i-1 
formulation, in which EGF was replaced by amphiregulin, 
and the two additives cholera toxin and hydrocortisone were 
omitted in the TGFb2i medium. These changes allowed 
instant serial-passage growth of both normal ER+ cells and 
MCF7 cells under identical conditions. To the best of my 
knowledge, hTERT/shp16 immortalized ER+ cells with this 
strict luminal profile have not been previously available 
which could be compared to the iconic MCF7 cancer cells 
under identical culture conditions. Interestingly we found 
that these cell lines were classified as progenitors based on 
expression arrays [86]. These cell lines also showed other 
interesting differences when compared to the MCF7 cell line. 
Nevertheless, we are now able to utilize these cells for a 
multitude of downstream applications. 
Conclusion and Future prospective 
As we have reviewed here ER+ luminal cells are 
detrimental to glandular growth in the human breast. How 
exactly the signal is translated from systemic ovarian 
hormone levels in the blood to proliferation in breast tissue is 
still largely unknown within a human context. With such 
large differences between the stromal compartments of mice 
and humans requires us to reevaluate the intralobular stroma 
with respect to a specific role in the TDLUs, and thus, as a 
potential partner in organoid cultures for the maintenance of 
luminal structure and function. However, cell models derived 
from normal breast tissue displaying intact functioning ER+ 
signaling networks have remained largely unexplored until 
now. “Zero to one” may sound overly enthusiastic, however, 
we have developed a robust reproducible protocol for ER+ 
cells proliferating in culture. A long line of important 
questions remains to be answered. For example, why do 
normal cells segregate into proliferating and resting ER+ 
cells, a feature which seems to be disrupted in breast cancer? 
What aspects of the stromal compartment are responsible for 
the separation these compartments? Is an aberrant stromal 
regime responsible for discrepancies shown in TGFβ 
signaling in cancer? Currently, we are pursuing cell polarity 
and the segregation of ER and proliferation as readouts in 
screens for early transformation. What is needed next is the 
enigmatic organoid culture allowing for both structural and 
functional differentiation. Hopefully, these novel cell lines 
can help answer some of the questions of how luminal ER+ 
breast cancer develops in hopes to design therapeutic or even 
prophylactic strategies against this prevalent subtype of 
breast cancer. 
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